High-efficiency electrochemical degradation of antiviral drug Abacavir (cas 136470-78-5) using a penetration flux porous Ti/SnO2–Sb anode
-
Add time:09/03/2019 Source:sciencedirect.com
Electrochemical degradation of antiviral drug Abacavir (cas 136470-78-5) was investigated by using a penetration flux porous Ti/SnO2–Sb anode prepared by sol-gel method. The effects of applied current density, initial pH, and inorganic anions on the degradation kinetics were systematically studied. Degradation efficiency more than 97% was performed in only 10 min at a current density of 0.2 mA cm−2. The corresponding degradation rate constant and the lowest electrical energy per order were calculated to be 0.36 min−1 and 6.5 mWh L−1, respectively. Extending the reaction duration to 5 h, 53.3% of TOC removal was observed. The results indicated that effective degradation of abacavir appeared in the penetration flux porous Ti/SnO2–Sb anode with a very low energy consumption. Furthermore, the electrochemical intermediate products and the reaction site during abacavir degradation were detected and recognized. The quantitative structure-activity relationship model revealed that the potential risks of abacavir to the aquatic organism, such as fish, greatly decreased after flowing through the penetration flux porous Ti/SnO2–Sb anode.
We also recommend Trading Suppliers and Manufacturers of Abacavir (cas 136470-78-5). Pls Click Website Link as below: cas 136470-78-5 suppliers
Prev:Brief communicationLow frequency of hypersensitivity reactions to Abacavir (cas 136470-78-5) in HIV infected patients in a referral center in Bahia, Brazil
Next:Case reportAbacavir (cas 136470-78-5)-induced liver toxicity) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Monitoring Abacavir (cas 136470-78-5) bioactivation in humans: Screening for an aldehyde metabolite09/10/2019
- Effect of drug efflux transporters on placental transport of antiretroviral agent Abacavir (cas 136470-78-5)09/09/2019
- Abacavir (cas 136470-78-5) and cardiovascular disease: A critical look at the data09/08/2019
- Abacavir (cas 136470-78-5)☆09/07/2019
- Original articleSwitching from Abacavir (cas 136470-78-5)/lamivudine plus nevirapine to Abacavir (cas 136470-78-5)/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study)Abacavir (cas 136470-78-5)/lamivudine/dolutégravir après Abacavir (cas 136470-78-5)/lamivudine plus névirapine chez des adultes infectés par le VIH et contrôlés virologiquement (étude SWAD)09/06/2019
- ReviewRisk of cardiovascular disease associated with exposure to Abacavir (cas 136470-78-5) among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies09/05/2019
- Case reportAbacavir (cas 136470-78-5)-induced liver toxicity09/04/2019
- Brief communicationLow frequency of hypersensitivity reactions to Abacavir (cas 136470-78-5) in HIV infected patients in a referral center in Bahia, Brazil09/02/2019